Evaluation of Long-term Efficacy and Safety for Hybrid Stent and Exclusive Drug Eluting Stent Implantation for Treating the Patients With Multi-lesion Coronary Disease
10.3969/j.issn.1000-3614.2014.07.004
- VernacularTitle:混合置入药物洗脱支架和裸金属支架治疗多处冠状动脉病变的远期疗效和安全性评价
- Author:
Yiping LI
;
Dong ZHANG
;
Kefei DOU
;
Bo XU
;
Yuejin YANG
;
Jue CHEN
;
Haibo LIU
;
Min YAO
;
Xuewen QIN
;
Yongjian WU
;
Jianjun LI
;
Shubin QIAO
;
Shijie YOU
;
Jilin CHEN
;
Runlin GAO
- Publication Type:Journal Article
- Keywords:
Drug Eluting stent;
Bare Metal stent;
Efifcacy;
Safety
- From:
Chinese Circulation Journal
2014;(7):492-496
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the hybrid of drug eluting stent (DES) with bare metal stent (BMS) and exclusive DES implantation for treating the patients with multi-lesion coronary disease.
Methods: A total of 6495 patients with multi-lesion coronary disease received elective PCI in our hospital from 2004-04 to 2006-10 were retrospectively studied. The patients were divided into 2 groups, Hybrid group, n=848 and Exclusive DES group, n=5647. With 1:1 propensity score matching, there were 823 pair of patients were ifnally studied. The clinical outcomes included 1, 2 years post-operative all cause death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), major adverse cardiac events (MACE) and in-stent thrombosis. The relative risks of all outcomes were assessed by Cox’s proportional-hazard model after propensity match.
Results: With propensity match, Cox’s proportional-hazard model analysis indicated that compared with Exclusive DES group, Hybrid group had the higher risks of TLR (HR 2.38, 95%CI 1.50-3.70), TVR (HR 1.61, 95%CI 1.15-2.27), MACE (HR 1.37, 95%CI 1.02-1.85), all P<0.01. The all cause death, MI and the ratio of all cause death/MI were similar between 2 groups in 1, 2 years follow-up period, all P>0.05.
Conclusion:Compared with exclusive DES, the hybrid of DES with BMS implantation had the higher risk of TLR, TVR and MACE for treating the patients with multi-lesion coronary disease.
